Chronic toxicity and carcinogenicity studies of the long-acting GLP-1 receptor agonist dulaglutide in rodents

Endocrinology (United States)

Volumn 156, Issue 7, 2015, Pages 2417-2428

  Byrd, Richard A ^a   Sorden, Steven D ^b   Ryan, Thomas ^b   Pienkowski, Thomas ^b   LaRock, Richard ^b   Quander, Ricardo ^b   Wijsman, John A ^a   Smith, Holly W ^a   Blackbourne, Jamie L ^a   Rosol, Thomas J ^c   Long, Gerald G ^d   Martin, Jennifer A ^a   Vahle, John L ^a  

^a ELI LILLY AND COMPANY   (United States)

^b 206 Carnegie Center   (United States)

^c OHIO STATE UNIVERSITY   (United States)

^d EXPERIMENTAL PATHOLOGY LABORATORIES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCITONIN; CALCIUM; DULAGLUTIDE; ANTIDIABETIC AGENT; GLP1R PROTEIN, HUMAN; GLP1R PROTEIN, MOUSE; GLP1R PROTEIN, RAT; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON RECEPTOR; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; HYBRID PROTEIN; IMMUNOGLOBULIN FC FRAGMENT; PROTEIN P21;

ANGIOSARCOMA; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIBODY RESPONSE; AREA UNDER THE CURVE; ARTICLE; BODY WEIGHT; CALCITONIN BLOOD LEVEL; CARCINOGENICITY; CAUSE OF DEATH; CELL HYPERPLASIA; CELL VOLUME; CHRONIC TOXICITY; CONTROLLED STUDY; DRUG BLOOD LEVEL; FEMALE; FOOD INTAKE; HEMANGIOMA; HISTOPATHOLOGY; IMAGE ANALYSIS; IMMUNOHISTOCHEMISTRY; LUNG ALVEOLUS CELL CARCINOMA; MAXIMUM PLASMA CONCENTRATION; MORPHOMETRICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RAT; SQUAMOUS CELL CARCINOMA; STEADY STATE; SURVIVAL; THYROID PARAFOLLICULAR CELL; TOXICOKINETICS; AGONISTS; ANALOGS AND DERIVATIVES; ANIMAL; BLOOD; CARCINOGEN TESTING; CARCINOMA; CHEMICALLY INDUCED; DRUG EFFECTS; GENETICS; HYPERPLASIA; MALE; ORGAN SIZE; PATHOLOGY; SECRETION (PROCESS); THYROID GLAND; THYROID TUMOR; TRANSGENIC MOUSE;

ANIMALS; CALCITONIN; CARCINOGENICITY TESTS; CARCINOMA, NEUROENDOCRINE; FEMALE; GLUCAGON-LIKE PEPTIDE-1 RECEPTOR; GLUCAGON-LIKE PEPTIDES; HYPERPLASIA; HYPOGLYCEMIC AGENTS; IMMUNOGLOBULIN FC FRAGMENTS; MALE; MICE; MICE, TRANSGENIC; ORGAN SIZE; PROTO-ONCOGENE PROTEINS P21(RAS); RATS; RECEPTORS, GLUCAGON; RECOMBINANT FUSION PROTEINS; THYROID GLAND; THYROID NEOPLASMS;

EID: 84937597858     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2014-1722     Document Type: Article

References (33)

1. Nauck M. A critical analysis of the clinical use of incretin-based therapies: the benefits by far outweigh the potential risks. Diabetes Care. 2013;36:2126-2132.
2. Asmar M, Holst JJ. Glucagon-like peptide 1 and glucose-dependent insulinotropic polypeptide: new advances. Curr Opin Endocrinol Diabetes Obes. 2010;17:57-62.
3. Nauck MA, Heimesaat MM, Orskov C, Holst JJ, Ebert R, Creutzfeldt W. Preserved incretin activity of glucagon-like peptide 1 [7-36 amide] but not of synthetic human gastric inhibitory polypeptide in patients with type 2 diabetes mellitus. J Clin Invest. 1993;91:301-307.
4. Madsen LW, Knauf JA, Gotfredsen C, et al. GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. Endocrinology. 2012;153:1538-1547.
5. Knudsen L, Madsen LW, Andersen S, et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology. 2010;151:1473-1486.
6. European Medicines Agency. Assessment report for Victoza. 2009. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Public-assessment-report/human/001026/WC500050016.pdf. Accessed August 6, 2013.
7. European Medicines Agency. Bydureon: EPAR - European Public Assessment Report. 2011. http://www.ema.europa.eu/ema/index.jsp?curl=pages/includes/document/document-detail.jsp?webContentId=WC500108239&mid=WC0b01ac058009a3dc. Accessed August 6, 2013.
8. European Medicines Agency. European Public Assessment Report: Lyxumia. 2012. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR---Public-assessment-report/human/002445/WC500140449.pdf. Accessed June 5, 2013.
9. Rosol TJ. On-target effects of GLP-1 receptor agonists on thyroid C-cells in rats and mice. Toxicol Pathol. 2013;41:303-309.
10. Gier B, Butler PC, Lai CK, Kirakossian D, DeNicola MM, Yeh MW. Glucagon like peptide-1 receptor expression in the human thyroid gland. J Clin Endocrinol Metab. 2012;97:121-131.
11. Butler PC, Elashoff M, Elashoff R, Gale EA. A critical analysis of the clinical use of incretin-based therapies: are the GLP-1 therapies safe? Diabetes Care. 2013;36:2118-2125.
12. Food and Drug Administration. Victoza (liraglutide injection): human relevance of rodent thyroid C-cell tumors. 2009. http://www.fda.gov/downloads/AdvisoryCommittees/Committees%20MeetingMaterials/Drugs/EndocrinologicandMetabolicDrugsAdvisoryCommittee/UCM151129.pdf. Accessed July 28, 2014.
13. Hegedüs L, Moses AC, Zdravkovic M, Le Thi T, Daniels GH. GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J Clin Endocrinol Metab. 2011;96:853-860.
14. Barrington P, Chien JY, Tibaldi F, Showalter HD, Schneck K, Ellis B. LY2189265, a long-acting glucagon-like peptide-1 analogue, showed a dose-dependent effect on insulin secretion in healthy subjects. Diabetes Obes Metab. 2011;13:434-438.
15. Glaesner W, Vick AM, Millican R, et al. Engineering and characterization of the long-acting glucagon-like peptide-1 analogue LY2189265, an Fc fusion protein. Diabetes Metab Res Rev. 2010;26:287-296.
16. Barrington P, Chien JY, Showalter HD, et al. A 5-week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long-acting glucagon-like peptide-1 analogue, in patients with type 2 diabetes. Diabetes Obes Metab. 2011;13:426-433.
17. Vahle J, Byrd R, Blackbourne J, et al. Effects of dulaglutide on thyroid C-cells and serum calcitonin in male monkeys. Endocrinology. 2015;156(7):2409-2416.
18. Morton D, Alden CL, Roth AJ, Usui T. The Tg rasH2 mouse in cancer hazard identification. Toxicologic Pathol. 2002;30:139-146.
19. Thomas DG, Breslow N, Gart JJ. Trend and homogeneity analyses of proportions and life table data. Comput Biomed Res. 1977;10:373-381.
20. Peto R, Pike MC, Day NE, et al. Guidelines for simple, sensitive significance tests for carcinogenic effects in long-term animal experiments. IARC Monogr Eval Carcinog Risk Chem Hum Suppl. 1980;(suppl 2):311-426.
21. Thakur AK, Berry KJ, Mielke PW. A FORTRAN program for testing trend and homogeneity in proportions. Comput Programs Biomed. 1985;19:229-233.
22. Tarone RE. Tests for trend in life table analysis. Biometrika. 1975;62:679-682.
23. Food and Drug Administration. Guidance for Industry: Statistical Aspects of the Design, Analysis, and Interpretation of Chronic Rodent Carcinogenicity Studies of the Pharmaceuticals. Rockville, MD: Center for Drug Evaluation and Research; 2001.
24. Ali MW. Exact versus asymptotic tests of trend of tumor prevalence in tumorigenicity experiments: a comparison of P values for small frequency of tumors. Drug Inf J. 1990;24:727-737.
25. European Medicines Agency. ICH Topic S1B, carcinogenicity: testing for carcinogenicity of pharmaceuticals. 2006. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500002735.pdf. Accessed July 9, 2014.
26. United States Food and Drug Administration. Tanzeum pharmacology review. 2013. http://www.accessdata.fda.gov/drugsatfda-docs/nda/2014/125431Orig1s000PharmR.pdf. Accessed January 29, 2015.
27. Tsai CL, Pu HF, Lau CP, Wang PS, Liu TK. Age-related differences in basal and calcium-stimulated plasma calcitonin levels in female rats. Am J Physiol. 1992;262(5 Pt 1):E557-E560.
28. Drucker DJ. The biology of incretin hormones. Cell Metab. 2006;3:153-165.
29. Körner M, Stöckli M, Waser B, Reubi JC. GLP-1 receptor expression in human tumors and human normal tissues: potential for in vivo targeting. J Nucl Med. 2007;48:736-743.
30. Vertongen P, Ciccarelli E, Woussen-Colle MC, De Neef P, Robberecht P, Cauvin A. Pituitary adenylate cyclase-activating polypeptide receptors of types I and II and glucagon-like peptide-I receptors are expressed in the rat medullary carcinoma of the thyroid cell line 6/23. Endocrinology. 1994;135:1537-1542.
31. Panjwani N, Mulvihill EE, Longuet C, et al. GLP-1 receptor activation indirectly reduces hepatic lipid accumulation but does not attenuate development of atherosclerosis in diabetic male ApoE(-/-) mice. Endocrinology. 2013;154:127-139.
32. Pyke C, Knudsen LB. The glucagon-like peptide-1 receptor - or not? Endocrinology. 2013;154:4-8.
33. Guerci B, Weinstock R, Umpierrez G, et al. Safety and efficacy of dulaglutide vs sitagliptin after 104 weeks in type 2 diabetes (AWARD-5). Diabetologia. 2013;56(suppl 1):S367.